Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
